Home » ArcherDx to Develop CDx for Celgene's Lymphoma Drug Candidate

ArcherDx to Develop CDx for Celgene's Lymphoma Drug Candidate

Nov 06, 2017
|
staff reporter

NEW YORK (Genomeweb) – ArcherDx announced on Monday an agreement to develop and commercialize a next generation sequencing-based companion diagnostic for Celgene's investigational drug CC-122 for diffuse large B cell lymphoma.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

What You Might Learn

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

From Whales to Urchins to Algae

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

In the Skin

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

This Week in PNAS

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Oct
04
Featured Webinar

Software Tools for NGS-Based Diagnosis of CFTR-Related Diseases in Routine Practice

Sponsored by
Agilent

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.